ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $33.00

ArriVent BioPharma (NASDAQ:AVBP) had its price target hoisted by Citigroup from $31.00 to $33.00 in a research report report published on Friday,Benzinga reports. Citigroup currently has a buy rating on the stock.

Several other research analysts have also weighed in on the stock. BTIG Research initiated coverage on shares of ArriVent BioPharma in a research report on Wednesday, December 10th. They set a “buy” rating and a $45.00 target price on the stock. Truist Financial initiated coverage on shares of ArriVent BioPharma in a research report on Tuesday, November 25th. They set a “buy” rating and a $43.00 price target for the company. Cantor Fitzgerald began coverage on ArriVent BioPharma in a research note on Monday, December 22nd. They set an “overweight” rating on the stock. Zacks Research upgraded ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a report on Friday, December 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.11.

ArriVent BioPharma Stock Down 7.2%

NASDAQ:AVBP opened at $23.43 on Friday. ArriVent BioPharma has a fifty-two week low of $15.47 and a fifty-two week high of $27.22. The stock has a market cap of $1.04 billion, a PE ratio of -5.31 and a beta of 0.98. The firm’s fifty day simple moving average is $22.20 and its 200-day simple moving average is $20.94.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.09. Equities analysts anticipate that ArriVent BioPharma will post -2.74 earnings per share for the current year.

Institutional Trading of ArriVent BioPharma

Several institutional investors and hedge funds have recently modified their holdings of AVBP. Bessemer Group Inc. acquired a new stake in shares of ArriVent BioPharma in the third quarter valued at approximately $26,000. Russell Investments Group Ltd. raised its position in shares of ArriVent BioPharma by 9,747.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 2,068 shares of the company’s stock worth $38,000 after purchasing an additional 2,047 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in ArriVent BioPharma by 27.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,006 shares of the company’s stock valued at $40,000 after buying an additional 438 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in ArriVent BioPharma by 31.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,571 shares of the company’s stock valued at $56,000 after buying an additional 609 shares during the last quarter. Finally, Group One Trading LLC purchased a new position in ArriVent BioPharma during the fourth quarter worth $57,000. Hedge funds and other institutional investors own 9.48% of the company’s stock.

Trending Headlines about ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $50 (from $44), a large upside vs. the current price. Oppenheimer boosts PT to $50
• Positive Sentiment: Citigroup raised its price target from $31 to $33 and kept a “buy” rating, signaling more analyst conviction. Citigroup raises PT to $33
• Positive Sentiment: HC Wainwright raised its target from $42 to $44 and maintained a “buy” rating—another analyst upgrade supporting upside. HC Wainwright raises PT to $44
• Positive Sentiment: Unusually large options activity: traders bought about 1,832 call contracts (≈321% above typical call volume), indicative of short-term bullish positioning.
• Positive Sentiment: Quarterly EPS beat: AVBP reported loss-per-share of ($0.78) vs. consensus ($0.87), a small beat that reduces near-term execution risk. Quarterly results press release
• Neutral Sentiment: Company released full-year 2025 financial results and highlighted progress; no headline surprises were reported in the summary notice. Full-year 2025 results
• Neutral Sentiment: Consensus brokerage coverage remains constructive (“Moderate Buy”), reflecting overall analyst support but not an immediate catalyst. Consensus recommendation coverage
• Neutral Sentiment: Reported short-interest entries show inconsistent/zero values (data artifact), so there’s no clear evidence of rising short pressure based on the published figures.
• Negative Sentiment: Despite the bullish signals above, AVBP is trading down on heavy volume — likely profit-taking, option-driven hedging flows, or broader market weakness outweighing analyst upgrades in the near term. Investors should watch intraday volume, near-term option activity, and any sector-wide moves for further direction.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.